Risk of COVID-19 Infection After Vaccination
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04848441 |
Recruitment Status :
Not yet recruiting
First Posted : April 19, 2021
Last Update Posted : April 19, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Vaccination; Infection Covid19 | Other: The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1 |
Study Type : | Observational |
Estimated Enrollment : | 2000000 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Risk of COVID-19 Infection After Vaccination: A Nationwide Study Comparing BNT162b2, mRNA-1273 and ChAdOx1 |
Estimated Study Start Date : | May 1, 2021 |
Estimated Primary Completion Date : | August 1, 2021 |
Estimated Study Completion Date : | August 1, 2021 |

- Other: The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1
The purpose of the study is to compare the effects of BNT162b2, mRNA-1273 and ChAdOx1 with respect to incident COVID-19 infection of different severities.
- Incident COVID-19 infection [ Time Frame: Up to six months after vaccination ]Four different severities: Being diagnosed, hospitalized, ICU-care and death within 30 days of diagnosis

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 0 Years to 110 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Living in Sweden and vaccinated with BNT162b2, mRNA-1273 or ChAdOx1
- All individuals with a previous COVID-19 infection
- Controls matched 1:1 to the groups above
Exclusion Criteria:
- None

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04848441
Contact: Peter Nordström, Prof | +46907851000 | peter.nordstrom@umu.se | |
Contact: Marcel Ballin, PhD | marcel.ballin@umu.se |
Responsible Party: | Umeå University |
ClinicalTrials.gov Identifier: | NCT04848441 |
Other Study ID Numbers: |
VACC-COV-19 |
First Posted: | April 19, 2021 Key Record Dates |
Last Update Posted: | April 19, 2021 |
Last Verified: | April 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Vaccination Nationwide observational study |
Infections Communicable Diseases COVID-19 Disease Attributes Pathologic Processes Respiratory Tract Infections Pneumonia, Viral Pneumonia |
Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |